Free Trial

ImmuPharma (LON:IMM) Shares Down 21.1% - Should You Sell?

ImmuPharma logo with Medical background

Key Points

  • ImmuPharma's stock price fell by 21.1%, trading at GBX 11.76 after opening as low as GBX 10.80.
  • The company reported a negative PE ratio of -1,446.18 and a negative return on equity of 131.41% for the last quarter.
  • ImmuPharma is focused on developing peptide-based therapeutics, with its lead program, P140 (Lupuzor™), aimed at treating Lupus and potentially other autoimmune diseases.
  • Five stocks we like better than ImmuPharma.

ImmuPharma plc (LON:IMM - Get Free Report)'s stock price was down 21.1% during trading on Thursday . The stock traded as low as GBX 10.80 ($0.15) and last traded at GBX 11.76 ($0.16). Approximately 45,915,910 shares changed hands during mid-day trading, an increase of 438% from the average daily volume of 8,530,393 shares. The stock had previously closed at GBX 14.90 ($0.20).

ImmuPharma Price Performance

The firm's fifty day simple moving average is GBX 4.28 and its 200 day simple moving average is GBX 3.27. The company has a market capitalization of £62.47 million, a PE ratio of -1,404.49 and a beta of 1.53.

ImmuPharma (LON:IMM - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported GBX (0.38) earnings per share (EPS) for the quarter. ImmuPharma had a negative return on equity of 131.41% and a net margin of 3,519.56%. On average, equities research analysts anticipate that ImmuPharma plc will post -339.0000022 EPS for the current fiscal year.

About ImmuPharma

(Get Free Report)

ImmuPharma PLC LSE AIM: IMM is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company's portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.

Featured Stories

Should You Invest $1,000 in ImmuPharma Right Now?

Before you consider ImmuPharma, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ImmuPharma wasn't on the list.

While ImmuPharma currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Analysts Agree—These Gold Picks Outshine the Rest Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report
Like this article? Share it with a colleague.